|
Malignant neoplasm of prostate
|
0.110 |
Biomarker
|
disease |
BEFREE |
Label-free quantification of EVs was performed to identify differentially expressed proteins between PCa and NAP.
|
31018022 |
2019 |
|
Malignant neoplasm of prostate
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
|
Memory performance
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
A genome-wide survey and functional brain imaging study identify CTNNBL1 as a memory-related gene.
|
22105620 |
2013 |
|
Body mass index procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
|
Finding of body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association with bone mass and geometry in the Framingham Heart Study.
|
17903296 |
2007 |
|
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association with bone mass and geometry in the Framingham Heart Study.
|
17903296 |
2007 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, aluminum ions may increase the risk for neurotoxicity in AD, and the use of NAP is suggested as a treatment to provide additional protection against the effects of aluminum ions, via EEA1 and PI3KR2, associated with sorting and processing of the AD amyloid precursor protein (APP) through the endosomal system.
|
30987727 |
2019 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Addressing Alzheimer's disease tangles: from NAP to AL-108.
|
19874271 |
2009 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]).
|
19245693 |
2009 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We found no evidence for an association of the reported variants in CTNNBL1 with early onset obesity or increased BMI.
|
19228371 |
2009 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of NAP on Abeta and tau pathology using a transgenic mouse model that recapitulates both aspects of AD.
|
17478890 |
2007 |
|
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, deepened characterization of NAP action mechanism on hyperglycemic-inflammatory damage may be useful to develop a new strategy to prevent retinal damage during DR.
|
30374973 |
2019 |
|
Impaired cognition
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
17% of human unique orthologues of mouse NAP genes are known loci for cognitive dysfunction.
|
31371714 |
2019 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we examined the potential preferential interaction of NAP with 3R vs. 4R Tau, toward personalized treatment of tauopathies.
|
30865715 |
2019 |
|
Diabetic Retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
More recently, we have shown that a small peptide derived from the activity-dependent neuroprotective protein (ADNP), known as NAP, counteracts damages occurring during progression of diabetic retinopathy by modulating HIFs/VEGF pathway.
|
28436035 |
2018 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Helicobacter pylori quantity and HP-NAP gene expression were evaluated in the faeces of healthy and asthmatic children.
|
28579087 |
2018 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.
|
28501461 |
2017 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
We previously investigated the disease-modifying potential of a microtubule-stabilising peptide NAP (NAPVSIPQ) in a well-established Drosophila model of tauopathy characterised by microtubule breakdown and axonal transport deficits.
|
27910888 |
2016 |
|
Impaired cognition
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.
|
26553741 |
2015 |
|
Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site
|
0.020 |
Biomarker
|
disease |
BEFREE |
To detect and evaluate the antibodies against Helicobacter pylori (H pylori) neutrophil-activating protein (HP-NAP) in patients with gastric cancer and other gastroduodenal diseases.
|
19452583 |
2009 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
LHGDN |
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
|
19148501 |
2009 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings tie for the first time a reduction in presynaptic glutamatergic synapses with the autism/Alzheimer's/schizophrenia-linked ADNP deficiency coupled with amelioration by NAP (CP201).
|
30664622 |
2019 |
|
Disorder of eye
|
0.010 |
Biomarker
|
group |
BEFREE |
NAP exerts a protective effect in various eye diseases, including DR.
|
30374973 |
2019 |